Search the GHTC website

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

October 27, 2011 by Kim Lufkin

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC member Bio Ventures for Global Health has released a new report that analyzes the engagement of different players in global health drug and vaccine development.

The world invested $630.4 million in tuberculosis research and development in 2010—less than one-third of the projected $2 billion annual investment needed to eliminate the disease as a public health threat by 2050—according to a new report. While spending rose slightly by two percent since 2009, it is the smallest year-on-year increase documented.

Funding from the National Institutes of Health supported more than 432,000 jobs and generated more than $62.1 billion in economic activity last year.

FSG and GBCHealth look at how pharmaceutical and medical device companies can create shared value in global health by addressing unmet health needs in low- and middle-income countries.

About the author

Kim LufkinGHTC

Kim Lufkin is a communications officer at GHTC.